DELVAMED
ActiveSummary
DELVAMED has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €67,342 and a net result of €64,113. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 27% of 17112 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Overview
What they do
General medical practice
NACE 86210
1 site
How big
€202,254total assets 2025
- Equity
- €67,342
- Profit
- €64,113
Turnover not published (abridged schema)
Who decides
Accounts 15 d early0 of 2 deeds read
Why 81- Limited track record+ Lower-failure-rate sector+ Annual accounts: healthy financial profileLatest accounts filed on timeShow the evidence
Checked score
Score 2025
Axes · tick = 2024
Profitability100=
Solvency58▼-42
Growth78=
Track record94
Bankruptcy probability, 12 months
0.2%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €5,000 at 30 days acceptable
Liquidity tight (current ratio 1.46 against 14.73 in 2024; short-term debt: 66.7% and cash: 80.8% of total assets), and 66.7% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Four signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 86
Relative position
BE, all sectors
reference
Human health activities (NACE 86)
about 87% fewer bankruptcies
← fewer bankruptcies
more bankruptcies →
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
33.3%
Return on assets
31.7%
Age of the figures
9 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 16-07-2026, 15 days ahead of the deadline.
NBB · 4 filingsDeviation from the deadline
2025
15 d early
2024
15 d early
2023
16 d early
2022
3 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 4 accounts on average 12 days before the deadline; the sector median for financial year 2024 is 7 days before the deadline, and 36% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 16 July (4 of the last 4 filed years within 30 days of that day).
Companies Code · seven monthsPosition in the running window
01-10-2026 today31-12-2026 close31-07-2027 deadline
- Annual accounts filedfiscal year 2025 · micro…
- Annual accounts filedfiscal year 2024 · micro…
- Highest result since 2022net €69,067 ▲10.7%
Financials
Fiscal year 2025Total assets €202,254Profit €64,113Solvency 33.3%Liquidity 1.46
Total assets
€202,254▲ 18.2%
2022 - 2025
Net result
€64,113▼ 7.2%
2022 - 2025
Equity
€67,342▼ 58.0%
2022 - 2025
Solvency
33.3%▼ 60.3pp
2022 - 2025
Financials · fiscal year 2025, micro schema
Trend over the years
Trend over the years
In euros
In per cent
Ratio
In euros
No line ticked in this group.
In per cent
No line ticked in this group.
Ratio
No line ticked in this group.
Untick a line to hide it. Point at a year (or use the arrow keys on the chart) for the exact figures; the table below gives them all.Sector: the middle half (P25 to P75) of NACE 86, Human health activities, each year against the same schema; no band under 30 filings. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA).
Every figure with its change against the fiscal year before
favourable
unfavourable
Line2022202320242025
Operating result€33,150-€78,889▲ 138%€88,255▲ 11.9%€82,090▼ 7.0%
Net result€26,280within the sector's middle half-€62,382within the sector's middle half▲ 137%€69,067within the sector's middle half▲ 10.7%€64,113within the sector's middle half▼ 7.2%
Equity€28,780below the sector's middle half-€91,162within the sector's middle half▲ 217%€160,229within the sector's middle half▲ 75.8%€67,342within the sector's middle half▼ 58.0%
Total assets€41,874below the sector's middle half-€106,717below the sector's middle half▲ 155%€171,110within the sector's middle half▲ 60.3%€202,254within the sector's middle half▲ 18.2%
Debt€13,095-€15,555▲ 18.8%€10,881▼ 30.0%€134,912▲ 1,140%
Working capital€25,579within the sector's middle half-€77,300within the sector's middle half▲ 202%€149,428within the sector's middle half▲ 93.3%€62,239within the sector's middle half▼ 58.3%
Solvency68.7%within the sector's middle half-85.4%above the sector's middle half▲ 16.7pp93.6%above the sector's middle half▲ 8.2pp33.3%within the sector's middle half▼ 60.3pp
Current ratio2.98within the sector's middle half-7.07above the sector's middle half▲ 4.0914.73above the sector's middle half▲ 7.661.46within the sector's middle half▼ 13.27
Return on assets (ROA)62.8%above the sector's middle half-58.5%above the sector's middle half▼ 4.3pp40.4%above the sector's middle half▼ 18.1pp31.7%within the sector's middle half▼ 8.7pp
above
within
below
the middle half (P25 to P75) of NACE 86, Human health activities, each year against the same schema; no band under 30 filings.
Turnover and EBIT margin not published: the micro schema does not require them.
Result and balance sheet
Result per fiscal year
Operating resultNet result
The operating result falls in 2025; 2025 is 7% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €202,254
Fixed assets
€5,103 ▼ 52.8%
Current assets
€197,151 ▲ 23.0%
Equity and liabilities €202,254
Equity
€67,342 ▼ 58.0%
Debt
€134,912 ▲ 1,140%
Debt's share of the balance-sheet total rises from 6.4% to 66.7%. Equity is lower and debt is higher.
Key figures and ratios
Key figures and ratios
EBITDA
€87,788▼
2024 · €94,143
Cash flow
€69,811▼
2024 · €74,955
Debt to equity
2.00▲
2024 · 0.07
ROE
95.2%▲
2024 · 43.1%
Interest coverage
366.06▼
2024 · 435.38
Debt ≤ 1 year
€134,912▲
2024 · €10,881
Income taxes
€17,737▼
2024 · €18,972
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 39,278 companies that looked in July 2024 the way this one looks now, 1.8% went bankrupt within 24 months and 96% are still going.
- Micro
- 2 to 5 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
1.8%
went bankrupt
2.3%
stopped otherwise
96%
still going
A further 0.1% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a lower bankruptcy probability: 0.2% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,341 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 1.0% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 39,278 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Filed annual accounts
Annual accounts
| Line | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €728 | €1,695 | €5,887 | €5,698 | ▼ 3.2% |
| Other operating charges640/8 | €93 | €310 | €497 | €1,024 | ▲ 106% |
| Gross operating margin9900 | €33,971 | €80,894 | €94,639 | €88,812 | ▼ 6.2% |
| Operating profit (loss)9901 | €33,150 | €78,889 | €88,255 | €82,090 | ▼ 7.0% |
| Financial income75/76B | €0 | €0 | - | - | - |
| Recurring financial income75 | €0 | €0 | - | - | - |
| Financial charges65/66B | €125 | €96 | €216 | €240 | ▲ 10.9% |
| Recurring financial charges65 | €125 | €96 | €216 | €240 | ▲ 10.9% |
| Profit (loss) for the period before taxes9903 | €33,026 | €78,792 | €88,039 | €81,850 | ▼ 7.0% |
| Income taxes67/77 | €6,746 | €16,410 | €18,972 | €17,737 | ▼ 6.5% |
| Profit (loss) for the period9904 | €26,280 | €62,382 | €69,067 | €64,113 | ▼ 7.2% |
| Profit (loss) for the period to be appropriated9905 | €26,280 | €62,382 | €69,067 | €64,113 | ▼ 7.2% |
| Line | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Assets | |||||
| Total assets20/58 | €41,874 | €106,717 | €171,110 | €202,254 | ▲ 18.2% |
| Fixed assets21/28 | €3,384 | €16,688 | €10,801 | €5,103 | ▼ 52.8% |
| Tangible fixed assets22/27 | €3,384 | €16,688 | €10,801 | €5,103 | ▼ 52.8% |
| Plant, machinery and equipment23 | €742 | €409 | €76 | €0 | ▼ 100% |
| Furniture and vehicles24 | €2,641 | €16,279 | €10,725 | €5,103 | ▼ 52.4% |
| Current assets29/58 | €38,491 | €90,029 | €160,309 | €197,151 | ▲ 23.0% |
| Cash at bank and in hand54/58 | €27,556 | €57,838 | €124,414 | €163,387 | ▲ 31.3% |
| Deferred charges and accrued income490/1 | €10,935 | €32,191 | €35,895 | €33,765 | ▼ 5.9% |
| Equity and liabilities | |||||
| Total equity and liabilities10/49 | €41,874 | €106,717 | €171,110 | €202,254 | ▲ 18.2% |
| Equity10/15 | €28,780 | €91,162 | €160,229 | €67,342 | ▼ 58.0% |
| Contributions10/11 | €2,500 | €2,500 | €2,500 | €2,500 | = |
| Reserves13 | €26,280 | €88,662 | €157,729 | €64,842 | ▼ 58.9% |
| Distributable reserves133 | €26,280 | €88,662 | €157,729 | €64,842 | ▼ 58.9% |
| Profit (loss) carried forward14 | - | - | - | €0 | - |
| Amounts payable17/49 | €13,095 | €15,555 | €10,881 | €134,912 | ▲ 1,140% |
| Amounts payable within one year42/48 | €12,912 | €12,728 | €10,881 | €134,912 | ▲ 1,140% |
| Trade debts44 | €1,234 | €1,173 | €550 | €5 | ▼ 99.1% |
| Suppliers440/4 | €1,234 | €1,173 | €550 | €5 | ▼ 99.1% |
| Taxes, remuneration and social security45 | €6,746 | €8,242 | €9,472 | €737 | ▼ 92.2% |
| Taxes450/3 | €6,746 | €6,410 | €9,472 | €737 | ▼ 92.2% |
| Remuneration and social security454/9 | - | €1,832 | €0 | - | - |
| Other amounts payable47/48 | €4,931 | €3,313 | €860 | €134,170 | ▲ 15,499% |
| Accrued charges and deferred income492/3 | €183 | €2,827 | €0 | - | - |
| Line | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €26,280 | €62,382 | €69,067 | €64,113 | ▼ 7.2% |
| + Depreciation and write-downs630 | €728 | €1,695 | €5,887 | €5,698 | ▼ 3.2% |
| Operating cash flow (approximation) | €27,008 | €64,078 | €74,955 | €69,811 | ▼ 6.9% |
| Investment in fixed assets (approximation) | - | -€15,000 | €0 | €0 | - |
| Change in cash | - | €30,282 | €66,576 | €38,973 | ▼ 41.5% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Comparable companies
Similar companies · same sector, comparable size
Dr. Geys Michèle
BE 0768.519.122
Mortsel · Eq €67,282
Docteur Anne Van Eyken
BE 1002.514.202
Elsene · Eq €67,181
Dr. Geubels Charlotte
BE 0802.821.389
Schilde · Eq €67,145
Manouk Lauwers
BE 0774.885.191
Ranst · Eq €67,585
POMARBO
BE 0762.800.476
Oostkamp · Eq €67,677
Of 9,130 companies in this sector we hold annual accounts for 6,339. 4,916 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Timeline
8 eventsLatest 16-07-2026Next filing 31-07-2027
History
Acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
16-07
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
16-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
31-12
Financial
Highest result since 2022net €69,067 ▲10.7%
Operating result €88,255, net result €69,067, both a record.
31-12
Financial
Liquidity doublescurrent ratio 14.73
Current ratio from 7.07 to 14.73; short-term debt falls from €12,728 to €10,881.
31-12
Financial
Equity above €150,000Eq €160,229 ▲75.8%
3 profitable years in a row build equity to €160,229.
15-07
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
31-12
Financial
Liquidity doublescurrent ratio 7.07
Current ratio from 2.98 to 7.07; short-term debt falls from €12,912 to €12,728.
28-07
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 2 acts read
About the unread acts
We know of 2 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Company details
Private limited company · founded 25-03-2022Year ends 31-12Peppol reachable1 site
Register details
Identification
Legal formPrivate limited company
Founded25-03-2022
Fiscal year end31-12
Activities, NACEBEL 2025
86210General medical practice
E-invoicing
Reachable via Peppol
Peppol ID
0208:0783821564
Also
9925:BE0783821564
Registered
02-09-2025
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 1 October 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.
Sites & property
Location & real-estate footprint
Registered office, Dilsen-Stokkem · 1 establishment unit since 2022
Ground area
2,599 m²
Building footprint
164 m²
Volume, LiDAR
704 m³
Parcel 72005B0735/00X000, Flanders · tallest building 6.3 m, ±1 floor. Linked by address, not a title deed.
2
companies at this address
See who is registered here
1 establishment unit
DELVAMED
since 2022unit no. 2.329.289.407
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 72005B0735/00X000 | Flanders | 2,599 m² | 1 · 164 m² | 6.3 m · 1 fl. |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.